Blujepa, the first new oral UTI antibiotic in 30 years, offers hope against antibiotic-resistant infections, improving ...
Good news for the millions of women who struggle with urinary tract infections (UTIs). The Food and Drug Administration (FDA) ...
The U.S. Food and Drug Administration (FDA) has approved GSK’s Blujepa (gepotidacin), a groundbreaking oral antibiotic for ...
Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes.
If you deal with recurrent UTIs, a new FDA-approved antibiotic called Blujepa could offer another treatment option—especially ...
GSK is opening the door to a new era in urinary tract infection (UTI) treatment with its Blujepa, the first in a new class of ...
A new antibiotic to treat stubborn urinary tract infection (UTI) and a blood-clot-dissolving intravenous treatment for acute ...
This antibiotic is the first new FDA-approved medication for urinary tract infections in decades, and meets the need for new ...
TUESDAY, March 25, 2025 (HealthDay News) — The U.S. Food and Drug Administration has approved Blujepa (gepotidacin) for the ...
The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections, the first such drug ...
Blujepa is the first in a new class of oral antibiotics in 30 years. It is expected to launch in the second half of 2025 in the United States.
Blujepa marks the first new oral antibiotic to gain FDA approval for uncomplicated urinary tract infections in nearly 30 ...